Lymphoma, B-Cell: all 1,415 studies
Page 3 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's LymphomaRecruitingNCT06104553Phase 1/2
- A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
- CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Phase 2
- A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
- Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCLNot yet recruitingNCT06062641Phase 2
- Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART StudyRecruitingNCT06052826Phase 2
- Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell LymphomaRecruitingNCT06047197Phase 1
- A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell MalignanciesRecruitingNCT06045910Phase 1/2
- JY231 Injection in the Treatment of Relapsed or Refractory B-cell LymphomaRecruitingNCT06045585Early Phase 1
- Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCLRecruitingNCT06033820Phase 2
- Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
- CD79b-19 CAR T Cells in Non-Hodgkin LymphomaRecruitingNCT06026319Phase 1
- CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)RecruitingNCT06002659Phase 1/2
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
- Obinutuzumab in Chinese Real-world Patients With iNHLNot yet recruitingNCT05968001
- Study of a Communication Training Intervention for Large B-Cell Lymphoma ProvidersRecruitingNCT05940272Not applicable
- Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
- Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell LymphomaNot yet recruitingNCT05909098Phase 1/2
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
- A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCLNot yet recruitingNCT05883709
- Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNCT05875428Phase 2
- A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete RemissionNot yet recruitingNCT05874778Phase 2
- Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
- Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05842707Phase 1/2
- Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis BiomarkersNot yet recruitingNCT05834426
- Frontline of ASCT in High-risk DLBCLRecruitingNCT05831865
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/2
- Decitabine and Anti-PD-1 in R/R DLBCLRecruitingNCT05816746Phase 2
- A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell LymphomaNot yet recruitingNCT05814848Phase 4
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell LymphomaRecruitingNCT05806580Phase 4
- Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's LymphomaRecruitingNCT05805943Phase 1/2
- Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin LymphomaRecruitingNCT05801913Phase 1
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHLNot yet recruitingNCT05779930Early Phase 1
- A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell LymphomasRecruitingNCT05773040Phase 1
- A Clinical Study of Injectable IMM0306 in Combination With LenalidomideNot yet recruitingNCT05771883Phase 1/2
- Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)Not yet recruitingNCT05746858
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLRecruitingNCT05702853Phase 1/2
- Chidamide in Patients With Recurrent and Refractory Diffuse Large bEnrolling by invitationNCT05690191
- Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05667155Phase 1
- CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCLRecruitingNCT05659628Phase 1
- Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell LymphomaNot yet recruitingNCT05651100Phase 1/2
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT05643742Phase 1/2
- TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHLRecruitingNCT05631912Phase 1/2
- A Compassionate Use (CU) Program of OdronextamabAvailableNCT05619367
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingNCT05615636Phase 2
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaRecruitingNCT05607420Phase 1/2
- Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial RemissionNot yet recruitingNCT05596097Phase 2
- Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaRecruitingNCT05590221Phase 2
- Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell LymphomaRecruitingNCT05585996Phase 1
- Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingNCT05577364Phase 1/2
- Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT05575973Phase 2
- Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
- Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase InhibitorsRecruitingNCT05495828
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesRecruitingNCT05476770Phase 1
- Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHLRecruitingNCT05472558Phase 1
- A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell LymphomasRecruitingNCT05463263Phase 1/2
- Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHLRecruitingNCT05453669Phase 1
- A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomaRecruitingNCT05444322Early Phase 1
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
- Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05436223Phase 2
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaRecruitingNCT05432635Phase 1
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma PopulationRecruitingNCT05376709Not applicable
- BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHLRecruitingNCT05370430Phase 1
- IKS03 in Patients With Advanced B Cell Non-Hodgkin LymphomasRecruitingNCT05365659Phase 1
- Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT05338931Phase 1/2
- Long-Term Follow-up StudyEnrolling by invitationNCT05332054
- Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin LymphomaRecruitingNCT05312801Phase 1
- Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaNot yet recruitingNCT05298293Not applicable
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 1
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
- The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsRecruitingNCT05179733Phase 3
- A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasEnrolling by invitationNCT05113069Phase 1
- CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRecruitingNCT05105867Early Phase 1
- Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsRecruitingNCT05098613Phase 1
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT05091541Phase 1/2
- Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCLRecruitingNCT05054426Phase 3
- Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell LymphomaRecruitingNCT05020392Phase 3
- A Study of LP-168 in Participants With Relapse or Refractory B-Cell LymphomaRecruitingNCT04993690Phase 1
- DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT04920617Phase 2
- CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT04892277Phase 1
- Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell LymphomaRecruitingNCT04887025Phase 1
- Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell TherapyRecruitingNCT04870853
- A Phase I/II Study of Diffuse Large B-cell LymphomaNot yet recruitingNCT04856137Phase 1/2
- Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)RecruitingNCT04824950Not applicable
- Phase Ib Clinical Study of KeynatinibRecruitingNCT04807881Phase 1